Bakert
05-18-2020, 10:40 AM
"A candidate vaccine for Covid-19 developed by the drug maker Moderna appears to generate an immune response similar to the response seen in people who have been infected by the virus and recovered, the company said Monday.
In a Phase 1 trial, eight patients who received two doses of the vaccine at the lowest and middle doses tested — 25 and 100 micrograms — developed neutralizing antibodies to the virus at levels similar to people who had recovered from infection, the company said in a statement.
The data were limited and from only a small number of participants in the trial, led by the National Institute of Allergy and Infectious Diseases. But they are still likely to be seen as encouraging. Research aimed to develop a vaccine against SARS, a related virus responsible for a 2002-2003 outbreak, showed that neutralizing antibodies are pivotal for achieving protection."
https://www.statnews.com/2020/05/18/early-data-show-moderna-covid-19-vaccine-generates-immune-response/
Another article noted:
"The company has said that it is proceeding on an accelerated timetable, with the second phase involving 600 people to begin soon, and a third phase to begin in July involving thousands of healthy people. The Food and Drug Administration gave Moderna the go-ahead for the second phase earlier this month."
https://www.nytimes.com/2020/05/18/health/coronavirus-vaccine-moderna.html?action=click&module=RelatedLinks&pgtype=Article
Moderna's stock price is up 22.57% today, from 66.69 to 82.16 after hitting a high shortly after opening of 86.30. For the past year Moderna has traded mostly in the $15 to $20 range.
In a Phase 1 trial, eight patients who received two doses of the vaccine at the lowest and middle doses tested — 25 and 100 micrograms — developed neutralizing antibodies to the virus at levels similar to people who had recovered from infection, the company said in a statement.
The data were limited and from only a small number of participants in the trial, led by the National Institute of Allergy and Infectious Diseases. But they are still likely to be seen as encouraging. Research aimed to develop a vaccine against SARS, a related virus responsible for a 2002-2003 outbreak, showed that neutralizing antibodies are pivotal for achieving protection."
https://www.statnews.com/2020/05/18/early-data-show-moderna-covid-19-vaccine-generates-immune-response/
Another article noted:
"The company has said that it is proceeding on an accelerated timetable, with the second phase involving 600 people to begin soon, and a third phase to begin in July involving thousands of healthy people. The Food and Drug Administration gave Moderna the go-ahead for the second phase earlier this month."
https://www.nytimes.com/2020/05/18/health/coronavirus-vaccine-moderna.html?action=click&module=RelatedLinks&pgtype=Article
Moderna's stock price is up 22.57% today, from 66.69 to 82.16 after hitting a high shortly after opening of 86.30. For the past year Moderna has traded mostly in the $15 to $20 range.